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Background: Hyperekplexia mutations have 
provided much information about glycine receptor 
structure and function. 
Results: We identified and characterized nine new 
mutations. Dominant mutations resulted in 
spontaneous activation whereas recessive 
mutations precluded surface expression. 
Conclusion: These data provide insight into 
glycine receptor activation mechanisms and surface 
expression determinants. 
Significance: The results enhance our 
understanding of hyperekplexia pathology and 
glycine receptor structure-function. 
 
ABSTRACT 
Hyperekplexia is a syndrome of readily 
provoked startle responses, alongside episodic 
and generalised hypertonia that presents within 
the first month of life. Inhibitory glycine 
receptors are pentameric ligand-gated ion 
channels (pLGICs) with a definitive and 
clinically well-stratified linkage to 
hyperekplexia. Most hyperekplexia cases are 
caused by mutations in the α1 subunit of the 
human glycine receptor (hGlyR) gene (GLRA1). 
Here we analysed 68 new unrelated 
hyperekplexia probands for GLRA1 mutations 
and identified 19 mutations of which nine were 
novel. Electrophysiological analysis 
demonstrated that the dominant mutations 
p.Q226E, p.V280M and p.R414H induced 
spontaneous channel activity indicating this is a 
recurring mechanism in hGlyR 
pathophysiology. p.Q226E, at the top of TM1, 
most likely induced tonic activation via an 
enhanced electrostatic attraction to p.R271 at 
the top of TM2, suggesting a structural 
mechanism for channel activation. Receptors 
incorporating p.P230S (which is heterozygous 
with p.R65W) desensitized much faster than 
wild type receptors, and represents a new TM1 
site capable of modulating desensitization. The 
recessive mutations p.R72C, p.R218W, p.L291P, 
p.D388A and p.E375X precluded cell surface 
expression unless co-expressed with α1 wild type 
subunits. The recessive p.E375X mutation 
resulted in subunit truncation upstream of the 
TM4 domain. Surprisingly, on the basis of three 
independent assays, we were able to infer that 
p.E375X truncated subunits are incorporated 
into functional hGlyRs together with unmutated 
α1 or α1 plus β subunits. These aberrant 
receptors exhibit significantly reduced glycine 
sensitivity. To our knowledge, this is the first 
suggestion that subunits lacking TM4 domains 
might be incorporated into functional pLGIC 
receptors.  
The glycine receptor chloride channel (GlyR), a 
member of the pentameric ligand-gated ion channel 
(pLGIC) family, mediates inhibitory 
neurotransmission in the spinal cord, brainstem and 
retina (1). Functional pLGICs comprise of homo- 
or hetero-pentamers with subunits arranged around 
a central ion-conducting pore (2). Each subunit 
contains an extracellular domain (ECD) harbouring 
the neurotransmitter binding site and a 
transmembrane domain (TMD) comprising four 
transmembrane α-helices (TM1-TM4) connected 
by flexible loops. A total of five GlyR subunit 
genes exist in humans (α1 – α4, β), although the α4 
(GLRA4) locus is considered a pseudo-gene due to 
a premature stop codon in the TM3-TM4 domain 
(3). Synaptic GlyRs comprise two α and three β 
subunits (4,5) although extrasynaptic homomeric α 
GlyRs are also found (6). Since the α1β GlyR is the 
sole stoichiometry responsible for inhibitory 
neurotransmission in motor reflex arcs of the spinal 
cord (6), mutations impairing the function of either 
the α1 or β subunit would be expected to impair 
motor performance. 
The evidence for the neuromotor role of the 
GlyR is provided by the unequivocal link between 
glycinergic genes and hyperekplexia, a rare 
neurological disorder (7,8). Hyperekplexia (also 
known as startle disease) is characterized by readily 
provoked startle responses, alongside a generalised 
and episodic hypertonia that presents within the 
first month of life. A proportion of cases have an 
increased likelihood of delay in speech acquisition, 
intellectual disability and recurrent neonatal and 
infantile apnoeas which gradually normalise during 
the first years of life. During development into 
adulthood the condition typically evolves into a 
life-long predisposition to excessive startle 
reflexes, triggered by unexpected auditory and 
tactile stimuli, which then cause startle-induced 
falls leading to repeated injuries. Hyperekplexia is 
caused not only by hereditary and de novo 
mutations in the human GlyR α1 and β subunit 
genes (7,9-13) but also by mutations in other 
proteins important for the formation and 
maintenance of glycinergic synapses (14-16). 
Mutations in the α1 and β subunits result in 
changes in the surface expression efficiency or in 
the functional properties of synaptic α1β GlyRs, 
thereby disrupting inhibitory neurotransmission in 
motor reflex circuits.  
We previously presented the results of a 
sequencing screen of the GlyR α1 subunit (GLRA1)   
in 88 unrelated hyperekplexia probands from where 
we identified a total of 19 mutations, twelve of 
which were novel (10). We demonstrated that 
dominant mutations typically disrupt receptor 
function without changing their surface expression 
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efficiency whereas recessive mutations generally 
preclude functional receptor expression when 
expressed either as mutated α1 homomers or as 
heteromers with the β subunit. In the present study, 
68 new unrelated patients with a clinical diagnosis 
of hyperekplexia were screened for mutations in 
GLRA1. The screening revealed a total of 19 
mutations of which nine were novel. All new 
mutations were characterized in terms of their 
electrophysiological properties and their cell 
surface localization. Additionally, a previously 
characterized mutation, p.R65W (10), was re-
investigated due to its presumed compound 
heterozygosity with the new mutation, p.P230S. 
The subsequent functional investigation of the 
hyperekplexia mutations revealed three residues 
critical for GlyR channel opening, providing 
insight into pLGIC activation mechanisms, and one 
novel residue playing an important role in 
desensitization.  
 
EXPERIMENTAL PROCEDURES 
 
Patient samples - A total of 68 unrelated probands 
with a clinical diagnosis of hyperekplexia were 
recruited for this study with appropriate ethical 
approval and consent procedures in place (South 
West Wales REC). Referral was initiated from 
neurologists, paediatricians, or clinical geneticists 
from the UK and several international centres. 
Diagnostic criteria for hyperekplexia included a 
non-habituating startle response (positive nose tap 
test), often with neonatal apnoea, a history of 
infantile hypertonicity, and clinical exclusion of 
phenocopies such as startle epilepsy or early 
encephalopathy (17,18). 
Molecular genetics - Multiplex PCR amplification 
(Qiagen, UK) was employed to rapidly amplify all 
coding exons and flanking intronic regions of 
GLRA1. Purified PCR amplimers were Sanger 
sequenced using ABITM capillary technology 
(Foster City, USA). The frequency of variants 
identified was determined by screening a panel of 
100 commercial control samples using restriction 
fragment length polymorphism (RFLP) if a suitable 
restriction enzyme was available, or by high-
resolution melt analysis performed on Lightscanner 
(Idaho Technologies, USA). Detection of large 
deletions or insertions was performed using 
Multiplex Ligation-Dependent Probe Amplification 
(MLPA, MRC-Holland) according to the 
manufacturer’s protocol. Additionally, 
confirmation of the recurrent exon 1-7 deletion 
mutation was carried out using a breakpoint PCR 
analysis (19). Mutations were introduced into 
pRK5-hGlyRα1 using the QuikChange site-
directed mutagenesis kit (Stratagene, UK) and 
confirmed by direct sequencing of the entire 
transgene-coding region (10).  
Fluorescence-based imaging - Experiments were 
performed on HEK AD293 cells cultured in 
Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal calf serum and 1% 
penicillin/streptomycin. The α1 wild type subunit, 
the β wild type subunit and the plasmids containing 
hyperekplexia mutations were all co-transfected in 
equal amounts. The pcDNA3-YFP-I152L plasmid 
was co-transfected in an amount equal to the sum 
of all transfected GlyR plasmid amounts. When the 
transfection was terminated 16 h later by rinsing 
with fresh culture medium, cells were plated into 
the wells of a 384-well plate. Within the following 
24 – 32 h, the cell culture medium was replaced by 
an extracellular control solution (140 mM NaCl, 5 
mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM 
HEPES, and 10 mM glucose, pH 7.4). Cells were 
imaged with an automated fluorescence-based 
screening system using YFP-I152L fluorescence 
quench as an indicator of anion influx rate (20). 
During experiments, fluorescence images of each 
well were obtained twice: once before and once 
after the application of a sodium iodide solution 
(140 mM NaI, 5 mM KCl, 2 mM CaCl2, 1 mM 
MgCl2, 10 mM HEPES, and 10 mM glucose, pH 
7.4) containing defined concentrations of glycine. 
Mean percentage quench values represent data 
averaged from four experiments carried out on 
different plates. Each experimental value was an 
average of the percentage quench of all fluorescent 
cells in three wells on the same plate, with each 
well containing > 200 cells. To determine the 
glycine dose-response curve from these data, an 
empirical three parameter Hill equation was fitted 
by a non-linear least squares algorithm using 
SigmaPlot 12.0 software.  
Electrophysiology - Glycine-gated currents were 
measured in HEK AD293 cells transfected as 
described above. Recordings were performed by 
whole-cell patch-clamp electrophysiology at a 
holding potential of -40 mV. Alternatively, 
spontaneous single-channel currents were recorded 
from outside-out excised patches, held at -70 mV in 
the absence of agonist, except for α1 wild type 
receptors, which opened too infrequently in 
glycine-free solution to obtain accurate estimates of 
current amplitude. Current amplitude for wild type 
receptors was instead estimated from recordings in 
the presence of 1 mM glycine. During experiments, 
cells were continually superfused with the 
extracellular control solution as detailed above. 
Patch pipettes were pulled to a final tip resistance 
of 1 – 4 MΩ (whole-cell) or 6 – 12 MΩ (outside-
out) when filled with a standard intracellular 
solution (145 mM CsCl, 2 mM CaCl2, 2 mM 
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MgCl2, 10 mM HEPES, and 10 mM EGTA, pH 
7.4). Whole-cell currents, which were filtered at 1 
kHz and digitized at 2 kHz, were recorded using an 
Axon MultiClamp 700B amplifier (Molecular 
Devices). Single-channel currents, filtered at 5 kHz 
and digitized at 20 kHz, were recorded using an 
Axon Axopatch 200B amplifier (Molecular 
Devices). Voltage-clamp fluorometry experiments 
were performed as previously described (21). 
Briefly, oocytes were removed from the ovaries of 
Xenopus laevis frogs, incubated in OR-2 (82.5 mM 
NaCl, 2 mM KCl, 1 mM MgCl2, and 5 mM 
HEPES, pH 7.4) containing 1.5 mg/ml collagenase 
for 2 h at room temperature on a shaker and co-
injected with 5 ng pGEMHE-hGlyRα1 and 25 ng 
pGEMHE-hGlyRα1-R271C/E375X RNA into the 
cytosol. Oocytes were cultured for 2 – 3 days at 18 
°C in ND96 (96 mM NaCl, 2 mM KCl, 1 mM 
MgCl2, 1.8 mM CaCl2, and 5 mM HEPES, pH 7.4) 
containing 275 mg/l sodium pyruvate, 110 mg/l 
theophylline and 0.1 % (v/v) gentamicin. For 
labelling, oocytes were incubated with 10 µM 
sulforhodamine methanethiosulfonate (MTSR) 
diluted in ND96 for 1 min on ice. 3 mM KCl was 
used as internal solution and recordings were 
performed at -40 mV. 
Immunofluorescence - GlyR α1 subunits were 
transiently expressed in HEK293 cells using the 
MagnetofectionTM method (Oz Biosciences). 
Around 24 h post-transfection, cells were fixed in 4 
% (w/v) paraformaldehyde (PFA) for 5 min at 
room temperature. Cells were quenched with 50 
mM NH4Cl in PBS. Fixed cells were permeabilised 
with PBS containing 0.1 % (v/v) Triton X-100 
(Sigma), 10 % (v/v) fetal calf serum (Sigma) and 
0.5 % (w/v) bovine serum albumin (fraction V; 
Sigma) to allow for intracellular immunostaining. 
Receptor sublocalization was determined using 
rabbit monoclonal anti-GlyR α1 (1:400, Millipore) 
primary antibody and with goat anti-rabbit 
secondary antibody, conjugated with AlexaFluor 
488 (1:200, Invitrogen). Cell surface 
immunostaining was conducted using the same 
reagents, antibodies and dilutions but carried out 
prior to PFA fixation. Fixed cells were then 
quenched with 50 mM NH4Cl before mounting on 
glass slides. Cell images were acquired using a 
Zeiss LSM 710 confocal microscope with ZEN 
software. The master gain was kept constant to 
compare the expression of α1 GlyR mutants 
relative to wild type. Transfection was repeated 
three times. 
Molecular modelling - Wild type and mutated 
forms of the human α1 GlyR were modelled by 50 
% homology (69 % sequence coverage) with PDB 
structure 3RHW, the glutamate-gated chloride 
channel receptor (α GluClR) from C. elegans (22). 
Using our multi-template homology modelling 
pipeline, this was one of three PDB homologues 
that were identified and used in the assembly of the 
α1 GlyR models, 3RHW (chain E), 1VRY (chain 
A) and 1MOT (chain A). The homology modelling 
pipeline was built with the Biskit structural 
bioinformatics platform (23). Our pipeline 
workflow incorporates the NCBI tools platform 
(24), including the BLAST program for similarity 
searching of sequence databases. T-COFFEE (25) 
was used for alignment of the test sequence with 
the template, followed by iterations of the 
MODELLER-9.11 program (26) to generate the 
final model structure. The Chimera program (27) 
was used for the viewing of models and generation 
of images. 
 
RESULTS 
 
Mutation analysis - A total of 68 probands with 
hyperekplexia were assessed for genetic variation 
in GLRA1 coding regions. All sequence variations 
were cross-referenced with the dbSNP database 
and our previous GLRA1 datasets (for recurrent 
mutations) and were regarded as probable 
mutations following exclusion from a panel of 100 
control samples and exome variants server 
(http://evs.gs.washington.edu/EVS/). The screening 
revealed 19 mutations in 21 hyperekplexia 
probands (Table 1), a rate which is consistent with 
previous studies (10,28). Nine mutations were 
novel in the public domain and three (one novel 
and two recurrent) mutations were present in more 
than one individual. Note that p.R414H has since 
been reported as a very rare variant in dbSNP 
(rs200130685), with a heterozygosity of 0.002 and 
a Minor Allele Frequency (MAF) of 0.0233 from 
the exome variants server. Consistent with previous 
studies, deletion and nonsense mutations were 
associated with recessive inheritance (homozygous 
or compound heterozygous) whereas missense 
mutations resulted in a dominant or recessive effect 
depending on their position in the polypeptide. The 
majority of index cases showed recessive 
inheritance (15 / 21; 71 %) including cases 12 and 
19 with confirmed compound heterozygosity as 
mutations were segregated back to parental DNA. 
It is likely that sample 5 represents a third case of 
compound heterozygosity; however, parental DNA 
was not available for confirmation. Four index 
cases of Turkish origin displayed a recessive 
homozygous deletion of exons 1-7 further 
confirming this deletion as a significant population-
specific risk-allele (10,29). Dominant mutations 
were mainly located in the discrete transmembrane 
α-helices whereas recessive mutations were spread 
throughout the protein. Phylogenetic alignment of 
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all novel missense mutations established that they 
altered conserved amino acids and were protein-
damaging when assessed using Sorting Intolerant 
from Tolerant (SIFT) tool (accessible at 
http://sift.jcvi.org/). The functional impact of the 
novel mutations was further investigated under 
recombinant conditions that simulated the 
dominant, recessive and compound heterozygous 
inheritance modes.  
 
Functional high-throughput analysis - The first 
round of functional characterization involved 
imaging live transfected cells via an automated 
fluorescence-based screening system using YFP-
I152L fluorescence quench as an indicator of anion 
influx rate (20). The advantage of this approach 
over electrophysiology is that responses of large 
cell numbers can be averaged, thus permitting the 
reliable quantitation of small changes in the 
functional expression levels of mutated GlyR 
isoforms. To investigate the functional properties 
of the mutated receptors, HEK AD293 cells were 
transiently transfected with wild type and mutated 
subunits in various combinations in an attempt to 
simulate dominant, recessive and compound 
heterozygous inheritance modes. Each mutated 
subunit was expressed on its own, with the β wild 
type subunit, with the α1 wild type subunit and 
with both α1 and β wild type subunits together. 
These experiments are summarized as: 1) mutant 
alone, 2) mutant + β, 3) mutant + α1, 4) mutant + 
α1β. For compound heterozygous mutations, the 
mutated subunits were also co-transfected together 
with and without the β wild type subunit, i.e., 5) 1st 
mutant + 2nd mutant, 6) 1st mutant + 2nd mutant + β. 
Fluorescent cells were considered as expressing 
functional GlyRs when the quench was a least 10 
% greater than the quench from cells expressing 
YFP only (no receptors).  
Glycine dose-response experiments showed that 
the glycine sensitivity was reduced for all recessive 
and compound heterozygous mutations relative to 
α1 wild type GlyRs (Fig. 1A). With the exception 
of the p.P230S mutation which expressed as a 
homomer, the recessive and compound 
heterozygous mutated subunits only showed a 
response to glycine if the α1 wild type subunit was 
co-expressed. Note that co-expression of these 
mutated α1 subunits with the β wild type subunit 
did not produce functional expression. Receptors 
incorporating both compound heterozygous 
mutations, p.L291P and p.D388A, showed no 
evidence of glycine sensitivity regardless of the 
presence of the β subunit. In contrast, receptors 
incorporating both p.R65W and p.P230S responded 
to glycine with and without β subunit co-
expression, albeit with dramatically reduced 
glycine sensitivity. As the glycine sensitivity was 
decreased for all mutated subunits when co-
expressed with the α1 wild type subunit, we 
concluded that all recessive and compound 
heterozygous mutated subunits were incorporated 
into functional GlyRs as heteromers, if not as 
homomers.  
For the three novel dominant mutations, in the 
case of p.R414H, no significant change in glycine 
EC50 was detected (Fig. 1A), and for receptors 
containing the dominant mutations p.Q226E and 
p.V280M, the glycine sensitivity could not be 
determined as fluorescence quench was complete 
in the absence of glycine. To test whether these 
three mutations formed spontaneously active 
channels, we initially bathed cells in NaCl solution 
and then introduced a high concentration of NaI 
solution containing no glycine. The results of this 
experiment, summarised in Fig. 1B, show that 
receptors containing p.Q226E, p.V280M or 
p.R414H subunits displayed significant quench in 
the absence of glycine. As iodide is highly 
permeant through GlyRs and quenches YFP-I152L 
fluorescence much more potently than chloride 
does, this result provides evidence that these three 
mutations result in spontaneously active or ‘leaky’ 
channels. Indeed, the high level of spontaneous 
activity was the reason why the glycine sensitivity 
of receptors incorporating p.Q226E and p.V280M 
mutations could not be quantitated (Fig. 1A).  
In addition, for all functional channels, the 
anion influx rate was significantly reduced relative 
to α1 wild type receptors as indicated by their 
reduced maximal glycine-induced fluorescence 
quench magnitude (Fig. 1C). As noted above, the 
fluorescence quench for p.Q226E- and p.V280M- 
containing GlyRs was already maximal in the 
absence of glycine. Moreover, the percentage of 
quenched cells relative to the total number of 
fluorescent cells was significantly reduced for all 
functional channels relative to α1 wild type 
receptors (except for p.R414H) suggesting that 
fewer functional receptors are located at the cell 
surface (Fig. 1D). This observation suggests that 
the mutations tend to impair functional receptor 
expression. 
 
Spontaneous activity as a mechanism for dominant 
hyperekplexia mutations - We then employed 
patch-clamp electrophysiology to analyse the 
effects of the mutations on receptor function at 
greater precision. Examples of currents activated 
by increasing glycine concentrations at homomeric 
α1 GlyRs together with the averaged glycine dose-
response relationship are shown in Fig. 2. The 
mean glycine EC50 value of p.Q226E indicates that 
the glycine sensitivity was not significantly altered 
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(Fig. 2A, Table 2). In contrast, for receptors 
incorporating the dominant mutation p.V280M, the 
sensitivity to glycine was dramatically increased 
relative to wild type receptors (Fig. 2B, Table 2). 
The mean glycine EC50 value of p.R414H was 
modestly increased (Fig. 2C; Table 2). These 
results are broadly consistent with the fluorescence 
data shown in Fig. 1. 
For the three novel dominant mutations, our 
fluorescence assay predicted spontaneous activity 
for p.Q226E, p.V280M and p.R414H receptors 
(Fig. 1B) which was then further investigated by 
recording single channel activity in outside-out 
membrane patches bathed in glycine-free 
extracellular solution. Recordings revealed 
spontaneous activity for all three mutated 
homomeric receptors whereas little, if any, 
spontaneous activity was ever observed for wild 
type α1 GlyRs (Fig. 3A) consistent with previous 
reports (30). At a membrane potential of -80 mV, 
the single channel current amplitude for p.Q226E 
receptors was smaller (4.5 ± 0.1 pA, n = 4 patches, 
Fig. 3B) than for wild type α1 receptors (7.2 ± 0.1 
pA, n = 3, Fig. 3A), whereas the amplitude for 
p.V280M receptors was unchanged (7.1 ± 0.2 pA, 
n = 3, Fig. 3C) and the magnitude of p.R414H 
receptors was larger (8.4 ± 0.2 pA, n = 3, Fig. 3D). 
The corresponding conductance values at −70 mV, 
a Cl− equilibrium potential of 0 mV, and a liquid 
junction potential of 4 mV, were; 97.3 pS, 60.8 pS, 
95.9 pS and 110.8 pS for wild type, p.Q266E, 
p.V280M and p.R414H receptors, respectively. 
Applying a saturating concentration of glycine, 
measuring the peak current response and dividing 
that by the single channel amplitude provided an 
estimate of the minimum number of channels 
contained in each recorded patch. Open probability 
(Po) was determined using segments of record that 
contained no evidence of multiple, superimposed 
openings. A total of 5 - 6 minutes of recording was 
selected across 3 - 4 patches for each channel type. 
Estimated Po values determined in this way should 
be regarded as upper limits and were as follows: 
p.Q226E, 0.03; p.V280M, 0.07; p.R414H, <0.001. 
Wild type homomeric receptors opened too 
infrequently in glycine-free solution to obtain a 
reliable Po measurement. It was, however, 
dramatically reduced relative to the mutated GlyRs. 
 
Incorporation of TM4 truncated subunits - 
Subunits incorporating the recessive mutations, 
p.R72C, p.R218W or p.E375X, were only 
functional when co-expressed with the α1 wild type 
subunit. The glycine sensitivities and the maximal 
current amplitudes of receptors incorporating these 
mutations were reduced relative to those of wild 
type receptors (Fig. 4A-D, Table 2) in agreement 
with the results from the fluorescence assay (Fig. 
1). For all α1β heteromeric receptors, β subunit 
incorporation was confirmed pharmacologically by 
its characteristic reduction in sensitivity to lindane 
inhibition (31) For example, in Fig. 4D (lower 
panel) we confirmed that α1 wild type GlyRs are 
strongly inhibited by 100 µM lindane, whereas α1β 
wild type GlyRs are resistant.  As receptors formed 
by co-expression of p.E375X, α1 wild type and β 
wild type subunits were also resistant to lindane 
and showed decreased glycine sensitivity relative 
to α1β GlyRs (Fig. 4D, Table 2), we infer that 
p.E375X subunits were incorporated into 
functional α1β heteromeric GlyRs. 
We were surprised to observe that the truncation 
mutation, p.E375X, which has lost the TM4 
domain, reduced the glycine sensitivity 
significantly (p < 0.001 relative to α1 wild type via 
unpaired t-test) when co-expressed with the α1 
wild type subunit (Fig. 4C, D). The reduced 
glycine sensitivity was only partly compensated by 
co-expressing the β wild type subunit. This result 
strongly suggests that the truncated subunit is 
incorporated into functional receptors which is 
unexpected given that previous GlyR studies 
indicated that TM4 deletion is incompatible with 
the surface expression of functional α1 GlyRs (32-
35). Given our unexpected result, we sought to 
confirm whether the p.E375X mutant subunit was 
incorporated into functional GlyRs using voltage-
clamp fluorometry. 
Voltage-clamp fluorometry involves 
introducing a cysteine into a receptor domain of 
interest and covalently tagging it with a sulfhydryl-
labelled fluorophore, commonly a rhodamine 
derivative such as MTSR. Because the quantum 
efficiency of rhodamine fluorescence is 
proportional to the hydrophobicity of its 
environment, a glycine-induced fluorescence 
change can be interpreted as a local conformational 
change at the labelled site (36). Voltage-clamp 
fluorometry is thus able to report conformational 
rearrangements in real time at defined locations on 
the surface of the labelled subunit. These 
experiments were performed on receptors 
expressed in Xenopus oocytes as HEK293 cells 
exhibit an unacceptably high level of non-specific 
MTSR labelling. The MTSR-labelled p.R271C 
mutant α1 GlyR produces a fluorescence change of 
~20 % upon activation with 10 mM (saturating) 
glycine (21). When the p.E375X truncation 
subunit, also labelled at p.R271C, was expressed 
together with the α1 wild type subunit, the 
activation of the recombinant receptors by 
saturating (10 mM) glycine generated currents with 
a mean maximal current amplitude of 4.8 ± 0.5 µA 
and a maximal change in fluorescence of 0.7 ± 0.1 
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% (n = 4; Fig. 4E). Control current and 
fluorescence traces from an MTSR-labelled 
p.R271C mutant GlyR are also shown. In contrast, 
unlabelled GlyRs comprising the same subunits 
yielded no significant glycine-induced fluorescence 
change (data not shown). This provides strong 
evidence for the surface expression of p.E375X 
subunits, and also suggests they experience a 
conformational change upon glycine-induced 
receptor activation. As the fluorescence change we 
observed is smaller than the change in fluorescence 
for homomeric p.R271C mutant α1 GlyRs (21), we 
infer that the p.E375X subunit is either 
incorporated into functional receptors at a low rate 
or that its conformational change is different from 
that of full length p.R271C α1 GlyRs. 
 
Functional effects in heterozygous state - Receptors 
incorporating the compound heterozygous mutation 
p.R65W showed drastically decreased glycine 
sensitivity and decreased maximal current 
amplitudes independent of β subunit expression 
(Fig. 5A; Table 2). The p.P230S mutation also 
decreased glycine sensitivity and maximal current 
amplitudes in the presence and absence of the β 
subunit (Fig. 5B; Table 2). All electrophysiological 
results for the p.R65W and p.P230S mutations are 
consistent with the fluorescence data described 
above (Fig. 1). It is also evident in Fig. 5B that 
p.P230S induces fast desensitization. These 
receptors exhibited a mean decay time constant of 
0.9 ± 0.3 s for 3 mM glycine (c.f., wild type 
receptors: 7.2 ± 1.7 s). Receptors containing the 
compound heterozygous mutations p.L291P or 
p.D388A were only functional when each mutated 
α1 subunit was co-expressed with the α1 wild type 
subunit (Fig. 1). Electrophysiological recordings 
revealed that the p.L291P mutation decreased 
glycine sensitivity but not maximal current 
amplitudes (Fig. 5C; Table 2). The p.D388A 
mutation decreased glycine sensitivity and maximal 
current amplitudes (Fig. 5D; Table 2). For both 
mutations, the changes relative to wild type 
receptors were independent of β subunit 
expression. Again, these results are consistent with 
the fluorescence data presented in Fig. 1. 
 
Cell surface localization - Confocal microscopy of 
transfected cells immunostained with an α1 GlyR 
antibody was performed to analyse subcellular 
localization of wild type and mutated receptors. 
Permeabilised cells were used to determine the 
intracellular sublocalization of receptors with all 
constructs showing comparable intracellular 
expression (Fig. 6, left hand image of each image 
pair). Cell surface expression was visualised in 
non-permeabilised cells. Cells transfected with 
wild type and the dominant mutations p.V280M 
and p.R414H showed immunoreactivity around the 
cellular circumference indicating localization at the 
surface (Fig. 6, right images), suggesting these 
variants do not affect integration of GlyRs into the 
cell membrane. The p.Q226E dominant mutation 
showed reduced immunoreactivity at the cell 
surface, suggesting it may impair integration into 
the surface membrane, unlike the other dominant 
mutations. The cell surface expression levels of 
recessive mutated receptors observed in this study 
showed partial or complete loss of cell surface 
accumulation. The recessive mutations p.R65W, 
p.P230S and p.L291P showed decreased 
integration into the surface membrane with only 
partial punctate staining, whilst p.R72C, p.R218W, 
p.D388A and p.E375X were completely absent 
from the cell membrane displaying only 
cytoplasmic staining (Fig. 6, right images). Surface 
accumulation of α1 subunits containing these 
mutations was not detectable with any of the three 
transfection procedures. 
 
Molecular modelling - A homology model based 
on the C. elegans α GluClR crystal structure was 
used to determine structural mechanisms by which 
novel mutations disrupted GlyR structure and 
function (Fig. 7). In particular, the spontaneously 
active channel p.Q226E affected the TM1 domain 
towards its extracellular end (Fig. 7A, B). 
Structural modelling showed extension of the TM2 
and TM3 helices at their extracellular end, along 
with extension of the TM4 helix at its intracellular 
end. Given that p.Q226E faces across the subunit 
interface towards p.R271 of the adjacent subunit 
(not shown), an enhanced electrostatic attraction 
between these two residues may be responsible for 
the tonic activity induced by p.Q226E. The other 
spontaneous opener p.V280M affected the 
extracellular loop between the TM2 and TM3 
domain (Fig. 7C). This mutation was also found to 
introduce a kink at the extracellular end of the TM1 
helix, perhaps via an altered energetic or steric 
interaction with I225 across the subunit interface. 
Also, the TM2 helix was extended at its 
extracellular end whereas the TM4 helix was 
extended at its intracellular end, along with a 
conformational change at this site. We also 
observed changes to the conformation of the 
extracellular domain. In the p.V280M receptor, the 
α-helix that is found in the wild type subunit 
between D12 and R20 was lost and a short helix 
was introduced around position 72 which would 
explain its dramatically altered glycine sensitivity. 
p.R414H affected the C-terminal region at the 
extracellular end of the TM4 domain causing 
profound loss of helical conformation at the 
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cytoplasmic end of the TM4 domain and extension 
of the TM2 helix at its extracellular end (Fig. 7D). 
Structural modelling suggested that the truncation 
mutation p.E375X, which lacks the TM4 domain, 
caused major conformational changes in the TM2 
helix via extension of the TM2 helix at its 
extracellular end and loss of the short helix at the 
top of the extracellular domain (Fig. 7E). The fast 
desensitizer p.P230S affected the TM1 domain, 
directly causing a major conformational change by 
introducing a profound kink at the extracellular end 
(Fig. 7F). In addition, a major conformational 
change at the cytoplasmic end of the TM3 helix 
was detected, producing another kink, and 
substantial changes to the TM4 helix. 
Conformational changes in the extracellular 
domain included loss of the short helix at the top 
and β sheet compression. 
The impact of the novel dominant mutations 
upon the pore radius is shown in Fig. 7G. For the 
spontaneously active receptors p.Q226E and 
p.V280M, a channel widening of 1.3 Å and 4.3 Å, 
respectively, at the cytoplasmic exit was detected 
relative to wild type receptors which is consistent 
with the observations of a leaky channel. In 
contrast, the mutation p.R414H had no effect on 
the pore diameter at the cytoplasmic exit but 
demonstrates substantial widening towards the 
extracellular entry explaining the observed 
spontaneous channel openings.  
 
DISCUSSION 
 
This study has identified a further 21 GLRA1-
positive hyperekplexia probands (Table 1) with 19 
mutations, of which nine were novel, adding to the 
compendium of GLRA1 mutations. Consistent with 
previous studies (10,37-40), dominant mutations 
were expressed at the cell surface thereby causing 
changes to the glycine sensitivity, conductance 
and/or open probability. In contrast, recessive and 
compound heterozygous mutations mainly affected 
cell surface trafficking and insertion of receptors 
into the membrane (10,41-43). The mechanisms by 
which each novel mutation caused hyperekplexia 
will now be considered in detail. 
Genetic screening identified three novel 
autosomal dominant mutations, p.Q226E, 
p.V280M and p.R414H, that each produced 
spontaneously active channels. Prior to this study, 
only one hyperekplexia mutation (Y128C) was 
known to produce spontaneous activity (10). This 
mutation was also autosomal dominant. 
Spontaneous activity was evident not only in 
mutated homomeric channels, but also in channels 
formed by the co-expression of mutated subunits 
and α1 wild type subunits and/or β wild type 
subunits (Fig. 1, 2). Structural modelling predicted 
that the mutations p.Q226E and p.V280M cause a 
widening of the outer channel pore leading to 
spontaneous activity. The p.V280M mutation 
dramatically increased both the level of 
spontaneous activity and glycine sensitivity, 
suggesting a drastic destabilisation of the closed 
channel state. The loss of the β sheet structure 
around the constraining loop C glycine binding 
domain is likely to impact upon glycine binding 
and retention, rendering the glycine binding site 
much more accessible. The kink introduced by 
p.V280M to the cytoplasmic end of the TM3 
domain affects the close TM2-TM3 packing, 
reducing the stability of the closed channel, due to 
greater conformational freedom at the cytoplasmic 
end of the TM2 domain. Given that p.V280M-
containing GlyRs expressed strongly at the cell 
surface (Fig. 6), the high level of spontaneous 
activity may partly explain the observed reduction 
in peak glycine-induced current magnitude. A 
reduction in the glycine-inducible current 
magnitude, coupled with a possible diminution of 
the chloride electrochemical gradient caused by the 
high level of spontaneous activity, may be among 
the mechanisms by which the p.V280M mutation 
disrupts glycinergic signalling.  
In contrast, the glycine sensitivities of p.Q226E- 
and p.R414H- containing receptors were similar to 
that of wild type receptors and both mutations 
caused spontaneous activity. However, modest 
reductions in the single channel conductance and 
the cell surface expression efficiency would have 
reduced the chloride flux-carrying capacity of 
p.Q226E-containing GlyRs and therefore may have 
contributed to the hyperekplexia phenotype (Fig. 
2D, 6). Given that p.Q226E is closely apposed with 
p.R271 of the adjacent subunit, we hypothesise that 
the enhanced electrostatic attraction between these 
oppositely-charged residues may be responsible for 
the tonic receptor activity. In the p.R414H GlyR, 
the extremely low spontaneous open probability 
seems unlikely to have caused a hyperekplexia 
phenotype on its own, as the expression efficiency 
and glycine sensitivity were not diminished relative 
to that of wild type receptors. One possibility is 
that the mutation altered TM4 orientation and thus 
TM3-TM4 loop structure, leading to a change in 
propensity of this subunit to bind clustering 
proteins at synapses. No effect on the predicted 
structure of the extracellular domain fits with wild 
type comparable glycine sensitivity seen for this 
mutation. However, the main difference to the wild 
type monomer is the loss of α-helical structure at 
the cytoplasmic end of the TM4 domain. This 
region is at the outside of the pentamer and 
contains an unusually high proportion of charged 
 9 
residues for a transmembrane region, 382-
QRAKKIDKISR-392, which is completely 
disrupted in p.R414H receptors.  
The recessive p.R72C, p.R218W and p.E375X 
mutations all precluded the surface expression of 
mutated homomeric GlyRs (Fig. 1, 4). However, 
when each mutated subunit was co-expressed with 
α1 wild type or α1 and β wild type subunits, robust 
glycine-activated currents were observed. As the 
glycine sensitivity of the resultant p.E375X 
receptor was significantly decreased relative to 
homomeric α1 GlyRs, we infer that the p.E375X 
subunit was incorporated into functional receptors 
together with either α1 subunits alone or with α1 
plus β subunits. Because this result was 
unexpected, it was substantiated using voltage-
clamp fluorometry (Fig. 4E). We also attempted to 
confirm it using immunofluorescence, but the 
incorporation rate may have been too low to allow 
surface expression to be detected. As noted above, 
we were surprised that the p.E375X subunit was 
incorporated given that previous studies have 
shown that TM4 deletion is incompatible with the 
surface expression of functional α1 GlyRs (32-35). 
Indeed, the deletion of only a few residues at the C-
terminal end of the TM4 domain is sufficient to 
render some pLGIC receptors completely non-
functional (12,44,45). 
To our knowledge, this is the first suggestion 
that a pLGIC receptor subunit may be functionally 
expressed without a TM4 domain. The human 
GlyR α4 subunit (Uniprot accession number 
Q5JXX5) has long been regarded as a pseudo-gene 
because it incorporates a stop codon that truncates 
the receptor prior to the TM4 domain (Simon et al., 
2004). The truncation occurs at the D383 residue 
which corresponds to Q382 in the α1 subunit. As 
this is C-terminal of E375, it is possible that the α4 
subunit may be incorporated into functional GlyRs 
suggesting it could exert a physiological role in 
modulating the functional properties of GlyRs. 
There may also be a case to reassess the 
pathophysiology of the other pLGIC late protein 
truncating events in epilepsy and related disorders, 
for example GABA type-A receptor mutations 
(46). 
Genetic analysis suggested possible 
heterozygosity between p.R65W and p.P230S 
although parental DNA was not available to 
confirm this. We previously described p.R65W as 
recessive on the basis of both the genetic analysis 
and a trafficking defect when expressed in the 
homozygous state (10). The present study shows 
that GlyRs comprised of p.R65W plus α1 and β 
wild type subunits exhibited a 20-fold increase in 
the glycine EC50 value (Fig. 1, 5). As this reduction 
in glycine sensitivity should be easily enough to 
cause hyperekplexia on its own (47,48), it implies 
that the p.R65W mutation should be inherited in an 
autosomal dominant manner. It therefore remains a 
mystery why heterozygous parents remain 
asymptomatic, possibly implying the existence of 
compensating physiological mechanisms. The 
p.P230S mutation produced fast desensitising 
receptors, reduced peak glycine-activated current 
magnitude and modestly reduced glycine 
sensitivity (Fig. 1, 5). All of these effects remained 
when the mutated subunit was co-expressed with 
α1 and/or β wild type subunits, implying that 
p.P230S should also exhibit an autosomal 
dominant inheritance mode. As expected, when 
p.R65W, p.P230S and β wild type subunits were 
co-expressed to mimic compound heterozygosity, 
glycine sensitivity and peak current magnitudes 
were drastically reduced (Fig. 1A, C), readily 
accounting for the hyperekplexia phenotype. 
As R65 forms a crucial component of the 
glycine binding site (5,49), the non-conservative 
p.R65W mutation most likely disrupts glycine 
binding when functionally expressed with wild 
type subunits. Our finding that it is not trafficked to 
the surface when expressed as a homomer (Fig. 1) 
is most likely the result of a global structural 
disruption caused by this mutation (10). As GlyR 
desensitization involves a specific conformational 
change at the ECD-TMD interface (50), the effect 
of the p.P230S mutation on desensitization may be 
due to a conformational change at this interface.  
Genetic analysis confirmed that the p.L291P 
and p.D388A mutations exhibited compound 
heterozygosity. Our functional analyses revealed 
that both mutated subunits did not express as 
homomers and exhibited reduced glycine 
sensitivity when individually co-expressed as 
heteromers with α1 and β wild type subunits (Fig. 
1, 5). We were unable to detect functional surface 
expression following co-expression of both 
p.L291P and p.D388A with β wild type subunits 
which would account for the hyperekplexia 
phenotype.  
In conclusion, this study illustrates the 
importance of hyperekplexia mutations in 
identifying new insights into the structure and 
function of GlyRs and other pLGIC family 
members. This in turn allows us to provide a more 
definitive explanation of the phenotype and clinical 
impact of the gene-positive patients through 
stratification of disease mechanisms. 
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FIGURE LEGENDS 
Fig. 1. Functional characterization of novel mutations using fluorescence-based imaging. A. Normalized 
glycine EC50 values for receptors comprised of the indicated subunit combinations. Results for p.Q226E and 
p.V280M containing GlyRs are not shown as complete quench occurred in the absence of glycine. For all 
other mutated receptors, the absence of a plotted result means that the indicated subunit(s) did not express. B. 
Mean percentage fluorescence quench observed when NaCl solution was replaced by NaI solution (without 
glycine). C. Normalized maximal changes in fluorescence observed upon the addition of NaI containing 
saturating glycine. The maximal change in fluorescence is presented as the final (quenched) fluorescence 
value minus the initial fluorescence value. D. Mean number of quenched cells expressed as a percentage of 
the total number of fluorescent cells. In panels A, C and D, all mutant values were normalised relative to the 
wild type value obtained from the same plate. In all panels, p-values were calculated relative to the α1 GlyR 
using one-way ANOVA followed by Dunnett’s post-hoc test: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p 
< 0.0001. 
Fig. 2. Functional characterization of autosomal dominant mutations by whole-cell and outside-out patch-
clamp recording. A. Sample whole-cell current recording for homomeric p.Q226E GlyRs. In this and all 
subsequent Figures, horizontal bars indicate the duration of the glycine applications with concentrations 
shown in µM. The right panel represents averaged whole-cell glycine dose-response curve for the p.Q226E 
GlyR. The α1 GlyR dose-response curve plotted here is replicated in all panels displaying dose-response 
curves in this and subsequent figures. B. Sample whole-cell current recording and averaged whole-cell 
glycine dose-response curve for the homomeric p.V280M GlyR. C. Sample whole-cell current recording and 
averaged whole-cell glycine dose-response curve for the homomeric p.R414H GlyR. Averaged parameters of 
best fit to all individual dose-response relationships are summarized in Table 2.  
Fig. 3. Single channel recordings of homomeric α1 wild type and spontaneously open mutant GlyRs. A. 
Single channel current recording of a patch expressing wild type receptors in the absence of glycine. Due to 
its low open probability in glycine-free solution, the higher resolution recording and accompanying 
amplitude histogram was obtained in 1 mM glycine. B. A sample recording of spontaneous single channel 
activity in an outside-out patch expressing p.Q226E, along with the amplitude histogram for the same patch. 
C. A sample single channel recording from a patch expressing p.V280M receptors, along with the amplitude 
histogram for the same patch. D. A sample single channel recording from a patch expressing p.R414H 
receptors, along with the amplitude histogram for the same patch. Channel openings are represented by 
downward deflections with the mean open current level indicated by dashed lines. The recordings in B-D 
were made in glycine-free solution. For these recordings, the activity above the horizontal bar in the lower 
resolution segment is reproduced at higher resolution below. Mean channel conductances and open 
probabilities are given in the text. 
Fig. 4. Functional characterization of autosomal recessive mutations by whole-cell patch-clamp recording 
and voltage-clamp fluorometry. A. Sample glycine dose-response trace for p.R72C GlyRs co-expressed with 
the α1 wild type subunit and normalized glycine dose-response relationship. B. Sample glycine dose-
response trace for p.R218W GlyRs co-expressed with the α1 wild type subunit and normalized glycine dose-
response relationship. C. Sample glycine dose-response traces for p.E375X GlyRs expressed together with 
α1 wild type or α1 wild type plus β wild type subunits as indicated. For this and all subsequent current 
recordings, unfilled bars represent the application of 100 µM lindane. The lack of lindane inhibition indicates 
strong expression of β subunits. The α1β GlyR dose-response curve plotted here is replicated in all dose-
response curve panels in Fig. 5. The bottom panel shows evidence for the efficient incorporation of β 
subunits into functional GlyRs. α1 homomeric GlyRs are strongly inhibited by 100 µM lindane (left), 
whereas α1β GlyRs are resistant (center panel). The right trace, recorded from the same cell as represented 
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above in panel C, shows that channels formed by the co-expression of p.E375X, α1 and β wild type subunits 
are also resistant to lindane. Using an unpaired t-test, mean lindane inhibition of these mutated receptors was 
significantly different to α1 (p < 0.001) but not to α1β receptors (p = 0.393). D. Normalized glycine dose-
response curves for α1 homomeric and α1β heteromeric receptors incorporating p.E375X. Averaged 
parameters of best fit to all individual dose-response relationships are summarized in Table 2. E. Sample 
current (black) and fluorescence (grey) responses induced by the application of 10 mM glycine in receptors 
comprising p.R271C/E375X and α1 wild type subunits and labelled with MTSR. Averaged results are 
summarized in the text. Control recordings from MTSR-labelled p.R271C GlyRs are also shown. 
Fig. 5. Functional characterization of compound heterozygous mutations by whole-cell patch-clamp 
recording. A. Sample glycine dose-response traces for p.R65W GlyRs expressed together with α1 wild type 
or α1 wild type plus β wild type subunits as indicated. Normalized glycine dose-response curves for 
receptors incorporating p.R65W subunits are shown below. B. Sample glycine dose-response traces for 
p.P230S GlyRs expressed either alone or with the β wild type subunit. Normalized glycine dose-response 
curves for receptors incorporating p.P230S subunits are shown below. C. Sample glycine dose-response 
traces for p.L291P GlyRs expressed together with α1 wild type or α1 wild type plus β wild type subunits as 
indicated. Normalized glycine dose-response curves for receptors incorporating p.L291P are shown below. 
D. Sample glycine dose-response traces for p.D388A GlyRs expressed together with α1 wild type or α1 wild 
type plus β wild type subunits as indicated. Normalized glycine dose-response curves for receptors 
incorporating p.D388A subunits are shown below. Averaged parameters of best fit to all individual dose-
response relationships are summarized in Table 2. 
Fig. 6. Expression of novel mutations using immunofluorescence. Images for intracellular expression (left) 
were taken as single cross-sectional confocal images and images for cell surface expression (right) as z-stack 
images. ++ indicates a high level of cell surface expression comparable with wild type; + indicates a 
reduction in cell surface expression in comparison to wild type (which was particularly dramatic in the case 
of p.R65W), and - indicates no visible expression. *R65W with increased master gain. 
Fig. 7. Structural modelling of novel mutations. A – F. Major conformational changes compared to wild type 
receptors are indicated by arrows. TM1 is shown in green, TM2 in blue, TM3 in yellow, TM4 in orange, 0’ 
(R252) in purple and helical extensions in red. G. Pore radius for wild type and three novel autosomal 
dominant mutations. Arrows indicate the limits of the membrane.
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Table 1. Details of hyperekplexia mutations identified in this study.  
Case Genotype Inheritance mode 
Class of 
mutation 
Protein 
mutation   
Protein 
position Gender Reference 
1 - 4 Exons 1-7 recessive deletion delEX1-7   
N-terminal-
M2 
2x male, 
2x female (29) 
5 
C573T 
compound 
heterozygote 
missense p.R65W 
} 
unknown N-terminal 
male 
(10) 
C1068T missense p.P230S unknown M1 novel 
6 - 7 C594T recessive missense p.R72C   N-terminal 2x female novel 
8 C1032T recessive missense p.R218W   N-terminal male novel 
9 G687A recessive missense p.E103K   N-terminal male (10) 
10 C971A recessive nonsense p.Y197X   N-terminal male (10) 
11 C986A recessive nonsense p.Y202X   N-terminal male (28) 
12 
G1033A 
compound 
heterozygote 
missense p.R218Q 
} 
paternal N-terminal 
male 
(51) 
C1267A nonsense p.S296X maternal M3 (52) 
13 C1056G dominant missense p.Q226E   M1 male novel 
14 G1135A recessive missense p.R252H   M1-M2  (53) 
15 - 
16 G1192A dominant missense p.R271Q   M2-M3 2x female (54) 
17 A1216G dominant missense p.Y279C   M2-M3 female (55) 
18 G1218A dominant missense p.V280M   M2-M3 male novel 
19 
T1252C 
compound 
heterozygote 
missense p.L291P 
} 
paternal M3 
female 
novel 
A1543C missense p.D388A maternal M3-M4 novel 
20 G1503T recessive nonsense p.E375X   M3-M4 male novel 
21 G1621A dominant missense p.R414H   C-terminal male rs200130685* 
 
* p.R414H was a novel variant at the time of identification but since it is listed as a very rare variant in 
dbSNP. 
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Table 2. Properties of novel mutations using whole-cell patch-clamp electrophysiology.  
 EC50  
(µM) 
nH 
Imax  
(nA) 
n 
wild type 
α1 64 ± 8 3.8 ± 0.3 19 ± 3 10 
α1β 39 ± 4 2.4 ± 0.2 14 ± 3 5 
dominant mutations 
p.Q226E 32 ± 6 3.5 ± 0.7 10 ± 5 3 
p.V280M 2.4 ± 0.3 1.1 ± 0.2*** 5 ± 4** 3 
p.R414H 110 ± 12 2.3 ± 0.2* 13 ± 1 4 
recessive mutations 
p.R72C + α1 189 ± 14 2.9 ± 0.1 8 ± 3* 4 
p.R218W + α1 235 ± 26 2.4 ± 0.2 6 ± 2** 4 
p.E375X + α1 243 ± 20 1.8 ± 0.2** 1.2 ± 0.4**** 4 
p.E375X + α1β 140 ± 22 2.2 ± 0.2 9 ± 4 3 
compound heterozygous mutations 
p.R65W + α1 1468 ± 557**** 1.0 ± 0.1**** 2.9 ± 1.3**** 6 
p.R65W + α1β 1281 ± 315**** 1.1 ± 0.2** 1.2 ± 0.9*** 5 
p.P230S 172 ± 50 1.6 ± 0.1**** 1.6 ± 0.5**** 6 
p.P230S + β 155 ± 26 2.4 ± 0.3 2.2 ± 1.0*** 6 
p.L291P + α1 198 ± 15 3.1 ± 0.5 9 ± 1* 5 
p.L291P + α1β 180 ± 22 2.2 ± 0.3 7 ± 1 4 
p.D388A + α1 173 ± 11 2.8 ± 0.7 6 ± 2** 5 
p.D388A + α1β 170 ± 16 2 ± 0.2 9 ± 3 4 
 
* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001  relative to the corresponding homo- or heteromeric 
wild type GlyR via one-way ANOVA followed by Dunnett’s post-hoc test. 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
R414H 
R414 
V280 
E375 
Q226 
L291 
D388 
R218 
R72 
R65 
Q226E 
V280M 
A 
P230S 
P230 
B C 
α1! α1-Q226E! α1-V280M!
D 
E F 
α1-R414H!
α1-E375X! α1-P230S!
po
re
 ra
di
us
 (Å
)  
distance along pore axis (Å) 
0"
1"
2"
3"
4"
5"
6"
7"
8"
-5 0 5 10 15 20 25 30 35 40 
WT 
Q226E 
V280M 
R414H 
cytoplasmic extracellular 
G 
α1"
α1-Q226E"
α1-V280M"
α1-R414H"
 
 
 
